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Abstract
Background: Hip effusion-synovitis may be relevant to osteoarthritis (OA) but is of uncertain etiology. The aim of
this study was to describe the cross-sectional and longitudinal associations of hip effusion-synovitis with clinical and
structural risk factors of OA in older adults.
Methods: One hundred ninety-six subjects from the Tasmanian Older Adult Cohort (TASOAC) study with a right
hip STIR (Short T1 Inversion Recovery) Magnetic Resonance Imaging (MRI) on two occasions were included. Hip
effusion-synovitis CSA (cm2) was assessed quantitatively. Hip pain was determined by WOMAC (Western Ontario
and McMaster Universities Osteoarthritis) while hip bone marrow lesions (BMLs), cartilage defects (femoral and/or
acetabular) and high cartilage signal were assessed on MRI. Joint space narrowing (0–3) and osteophytes (0–3)
were measured on x-ray using Altman’s atlas.
Results: Of 196 subjects, 32% (n = 63) had no or a small hip effusion-synovitis while 68% (n = 133) subjects had a
moderate or large hip effusion-synovitis. Both groups were similar but those with moderate or large hip effusion-
synovitis were older, had higher BMI and more hip pain. Cross-sectionally, hip effusion-synovitis at multiple sites
was associated with presence of hip pain [Prevalence ratio (PR):1.42 95%CI:1.05,1.93], but not with severity of hip
pain. Furthermore, hip effusion-synovitis size associated with femoral defect (βeta:0.32 95%CI:0.08,0.56).
Longitudinally, and incident hip cartilage defect (PR: 2.23 95%CI:1.00, 4.97) were associated with an increase in hip
effusion-synovitis CSA. Furthermore, independent of presence of effusion-synovitis, hip BMLs predicted incident (PR:
1.62 95%CI: 1.13, 2.34) and worsening of hip cartilage defects (PR: 1.50 95%CI: 1.20, 1.86). While hip cartilage defect
predicted incident (PR: 1.11 95%CI: 1.03, 1.20) and worsening hip BMLs (PR: 1.16 95%CI: 1.04, 1.30).
Conclusions: Hip effusion-synovitis at multiple sites (presumably reflecting extent) may be associated with hip pain.
Hip BMLs and hip cartilage defects are co-dependent and predict worsening hip effusion-synovitis, indicating causal
pathways between defects, BMLs and effusion-synovitis.
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Background
Osteoarthritis (OA) is characterized by alterations in
composition, structure and function of the various com-
ponents of joint, including synovium [1–4]. OA has been
historically categorized as non-inflammatory arthritis [2, 4].
However, synovitis plays a key role in cartilage damage and
vice versa [1, 2, 5]. Occurring in either early or late stages
of OA, synovitis leads to increase in catabolic and proin-
flammatory mediators such as cytokines, nitric oxide, pros-
taglandin E, and neuropeptides. These mediators produce
excess proteolytic enzymes, which cause cartilage matrix
degradation. In turn, cartilage breakdown leads to worsen-
ing synovitis [2, 6].
Several studies have reported associations of knee
effusion-synovitis proving that it is one of the causes of
knee pain, has an adverse effect on cartilage and is
linked with radiographic knee OA [3, 7–10]. Although
effusion-synovitis is a significant clinical prognostic fac-
tor for OA [11], at the hip it remains under-investigated.
A small retrospective study was the first to report hip
effusion in twelve out of twelve subjects and severe
synovitis in nine out of twelve subjects with hip RDOA
(Rapidly Destructive OA) but did not demonstrate corre-
lations of hip effusion or synovitis [12]. Subsequently, in
a clinical study, hip effusion was reported in 70% of the
subjects and major or/and asymmetrical hip effusion as-
sociated not only with hip pain but also with hip radio-
graphic OA (ROA) [13]. In a study, Magnetic Resonance
Imaging (MRI) was used for evaluating hip effusion and
synovitis separately, a weak association between grade 1
synovitis (but not grade 2) and hip pain was found.
However, in subjects with either synovitis or effusion, se-
vere hip ROA was prevalent [14]. In a retrospective
study, extensive synovitis was found in subjects with
RDOA than in those with hip OA, indicating that higher
synovitis could be related with rapid disease progression
[15]. Modest correlations between hip effusion and hip
ROA were demonstrated in a study designed to evaluate
hip OA. However, no association between hip effusion-
synovitis and hip pain score [16]. Interestingly, an MRI
study conducted in athletics demonstrated lower preva-
lence of effusion-synovitis in hips with pain than without
pain (Odds Ratio: 0.46 (95% CI: 0.3, 0.8) [17].
In a small study, investigating the effect of hyaluronic
acid (HA) in injection in those with and without hip OA
reported that hip pain was correlated with effusion-
synovitis (r = 0.27, p = 0.03) and was lower in partici-
pants injected with HA (13.9 vs 7.8, P < 0.001) [18]
Another study, showed that the frequency of effusion
(p = 0.013) and reactive synovitis (p < 0.001) was greater
in those with cam impingement [19].
Overall, the etiology of hip effusion-synovitis is under-
reported, and current data is inconclusive. Due to its
proximity to the hip cartilage and other structures, hip
effusion-synovitis could be a significant progenitor of
hip OA. Effusion-synovitis could be a potential target for
future clinical trials [20]. Hence, this study aims to de-
scribe the cross-sectional and longitudinal associations




The Tasmanian Older Adult Cohort (TASOAC) study is
an ongoing prospective, population-based study initiated
in 2002 and has been extensively described in previous
studies [21]. During the TASOAC study, a hip protocol
was added during the latter part of phase 2. Hip MRI
scans for phase2 and phase3 were conducted approxi-
mately 2.3 years apart. In the current study a sample of
245 consecutive participants who had a STIR (Short T1
Inversion Recovery) MRI sequence at phase 2 and/or
phase 3 were included. Of these 245 participants, 30 par-
ticipants were lost to follow-up in phase 3 and 17 sub-
jects had no STIR MRI at phase 2. Of 198 subjects, hip
effusion-synovitis could not be adequately assessed in
the MRI scans of 2 subjects and these were excluded.
Accordingly, a total of 196 subjects with complete data
were included in this study. Written informed consent
was obtained from all participants and the Southern
Tasmanian Health and Medical Human Research Ethics
Committee approved this study (approval number:
H6488).
Clinical and hip pain measures
Height, weight, Body mass index (BMI) were measured
using standard protocols. Hip pain was determined using
a hip specific Western Ontario and McMaster Universities
osteoarthritis (WOMAC) index pain score. WOMAC uses
a ten-point scale from 0 (indicating no pain) to 9 (indicat-
ing severe pain). Hip pain (five items) was assessed using
the following questions: ‘Referring to your hips only, how
much pain did you experience when walking on flat sur-
face, going up and down the stairs, at night while in bed,
sitting or lying, and standing upright.’ These five items
were summed to create a total hip pain score, each with a
possible range from 0 to 45 [22].
Magnetic resonance imaging (MRI) assessment
For those with a hip MRI, the right hip was imaged in
the sagittal plane using a 1.5 Telsa G. E signal whole-
body magnetic resonance unit with a phased-array flex
coil. Two MRI sequences were conducted for each par-
ticipant. Sagittal images were obtained at a partition
thickness of 1.5 mm with an in-plane resolution of
0.39 × 0.39 mm (512 × 512 pixels) using, a T1-weighted,
fat-suppressed, 3-dimensional gradient-recalled acquisi-
tion in the steady state. The parameters for this were:
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flip angle 55 degrees; repetition time 58ms; echo time 12
ms; inversion time (IT) 130ms; field of view 16 cm; 60
partitions; 512 × 512–pixel matrix; acquisition time 11
mins 56 s, and one acquisition [23]. A second set of sagit-
tal images was obtained with a slice thickness of 3.5 mm
and an inter-slice gap of 1.5 mm using a STIR-weighted,
fat saturation two-dimensional fast spin echo sequence.
This sequence used a repetition time 4340ms, echo time
28.4ms; field of view 20 cm; 15 partitions (16 slices) and
512 × 512 pixel matrix [24]. All MRI measures were con-
ducted on STIR MRI sequence using OsiriX imaging soft-
ware (University of Geneva, Geneva, Switzerland).
Quantitative assessment of hip effusion-synovitis
For quantitative measurements of hip effusion-synovitis,
the observer (HA) selected the MRI slice with the largest
effusion-synovitis and measured the maximum cross-
sectional area (CSA) by drawing contours around the
outer edges (Fig. 1). If the effusion-synovitis was present
at more than one site around the femoral head (anterior,
posterior or both), then the largest CSA of effusion-
synovitis on each site was assessed. The reproducibility
was evaluated in 40 subjects, with a 4 weeks interval be-
tween the two measures. The intra-rater agreement
(kappa) for the presence of hip effusion-synovitis was 0.84,
and the intra-class correlation coefficient (ICC) for hip
effusion-synovitis CSA was 0.97. We have used similar
method to assess knee hip effusion-synovitis [8] and also
used these measurements in previously published studies
[25, 26]. For analyses, the population was divided into two
groups by median of effusion-synovitis CSA. The first
group included subjects with no or small (< 0.77cm2) hip
effusion-synovitis and the second group included subjects
with moderate or large hip effusion-synovitis (≥0.77cm2).
Assessment of hip cartilage defects, hip BMLs, and high
cartilage signal
Hip cartilage defects were assessed on MRI using OsiriX
(Fig. 2). Hip defects on either femoral head or
acetabulum were identified as any change in the hip car-
tilage and were categorized as; grade 0 = normal cartil-
age, grade1 = focal blistering or irregularities on the
cartilage surface or a partial thickness defect and
grade2 = full-thickness defect with bone ulceration and/
or exposure of bone. If more than one defect was
present at one site, the highest score was used. In a reli-
ability study of 40 subjects with re-measurements after 4
weeks, the intra-rater agreement (kappa) was 0.89. Fur-
thermore, the inter-rater reliability (kappa) assessed by
two readers (n = 40) for the presence of cartilage defects
and defect categories was 0.84 and 0.63 respectively [25].
Hip BMLs were identified as areas of increased signal
intensity adjacent to the subchondral bone on the fem-
oral head and/or the acetabulum. The observer manually
selected the MRI slice with the largest BML and then
determined the BML size (cm2) (Fig. 2). Intra-observer
repeatability was assessed and the intra-class correlation
coefficient (ICC) of the hip, femoral and acetabular
BMLs was 0.98, 0.96 and 0.99 respectively [24].
High cartilage signal intensity change [27, 28] was de-
fined as a high signal intensity band within the hip car-
tilage either adjacent to a hip BML or at any location on
the STIR MRI slice if there was no BML present (Fig. 2).
The intra-rater agreement (kappa) was 0.88 [24].
Methods for assessing hip cartilage defects, hip BMLs
and cartilage were adapted by previously published grad-
ing systems used for assessment of structural changes in
the knee detected by MRI [21, 29–32].
Hip radiographs
Antero-posterior weight-bearing radiographs of the pel-
vis were obtained. Hip x-rays were read by two trained
readers using the OARSI (Osteoarthritis Research Soci-
ety international) grading system. The radiographic fea-
tures of JSN and osteophytes of the right hip were
graded on a 4-point scale, ranging from 0 to 3 where
0 = no disease and 3 =most severe disease by using an
Altman’s atlas [33]. The intra-observer reliability for x-
Fig. 1 Assessment of hip effusion-synovitis using OsiriX imaging software
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rays was carried out in 40 subjects and the ICC scores
ranged from 0.60–0.87 [23, 34]. A non-zero score of ei-
ther JSN or osteophytes was regarded as evidence of hip
ROA. Thus, after combining JSN and osteophytes score,
the presence of hip ROA was defined as a total score of
1 or greater.
Statistical analysis
Ninety-four percent of the population had any hip
effusion-synovitis. We were unable to differentiate be-
tween physiological (e.g. normal joint fluid) and patho-
logical effusion-synovitis. Initial data-driven cut-off
points did not reveal any significant results.,
Differences in demographical characteristics between
participants who had no or small and moderate or large
hip effusion-synovitis was calculated by using unpaired
t-tests and chi-square tests (Table 1). Hip effusion-
synovitis was also analyzed by the number of sites af-
fected (independent of size) and continuously as CSA.
For cross-sectional analysis, log-binomial regression was
employed to estimate the association between presence of
hip pain, moderate/large hip effusion-synovitis and pres-
ence of hip effusion-synovitis at one or two/three sites.
For estimating the relationship between severity of hip
pain and categories of hip effusion-synovitis, linear regres-
sion of the logarithm of pain score on a binary covariate
for hip effusion-synovitis was used. Log-binominal
regression models were applied to investigate the associa-
tions between presence of hip BMLs, high cartilage signal,
hip cartilage defects, hip ROA and presence of hip
effusion-synovitis while linear regression was used to test
the relationship between these factors and hip effusion-
synovitis CSA. Associations between presence of hip
BMLs and presence of cartilage defects were also investi-
gated using similar models.
For longitudinal analyses, linear regression models
were administered to estimate the relationship between
change in hip pain and change in hip effusion-synovitis
CSA. Similarly, the association between change in preva-
lence of hip BMLs, hip cartilage defects, hip ROA (base-
line only) and change in hip effusion-synovitis CSA was
examined using linear regression. Log-binominal regres-
sion was employed to investigate if hip BMLs predicted
incident and worsening of cartilage defects and vice-
versa (from phase 2 to phase 3). All results were pre-
sented as prevalence ratios (PR) and the models were ad-
justed for age, sex, body mass index (BMI), hip BMLs
and hip cartilage defects as required. For cross-sectional
analysis only, data on subjects at phase 2 and phase 3
were combined in analyses, and the correlation between
repeated measurements on individuals was taken into
account by adjusting standard errors using the sandwich
(robust) estimator of variance [35, 36]. All statistical
tests were two-sided and p values < 0.05 were considered
Fig. 2 Measurement of hip BML, high cartilage signal and hip cartilage defects using OsiriX imaging software
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significant and were conducted using Intercooled Stata
12 for Mac (Stata Corp, College station, TX, USA).
Results
Overall, 196 participants from both phases were included
in these analyses and the characteristics of the population is
presented in Table 1. The population was split into two
groups by the median of effusion-synovitis size. Participants
with moderate/large effusion were older, heavier and
mostly males. Presence of hip pain was more common in
those with moderate/large hip effusion-synovitis, than in
those with small or no hip effusion-synovitis. However, no
differences were found in pain severity (hip pain> 0). For
the imaging markers, of the two groups 20% of participants
with small or no hip effusion-synovitis had a hip BML. Fur-
thermore, presence of high cartilage signal and radiological
hip OA was proportionate in both groups. Although those
with moderate or large effusion-synovitis had more defects,
no statistically significant differences were found.
Table 2 shows the cross-sectional associations between
the presence and severity of hip pain and categories of
hip effusion-synovitis. Overall, subjects with moderate/
large hip effusion-synovitis had 31% greater hip pain but
this association was not statistically significant. Never-
theless, those with hip effusion-synovitis at multiple sites
had 42% higher hip pain in comparison to those with
hip effusion- synovitis at only one site. Hip effusion-
synovitis did not associate with severity of hip pain.
Cross-sectionally, hip BMLs [(Prevalence Ratio (PR):
0.75 95%CI:0.36,1.60)], high cartilage signal (PR:1.01
95%CI:0.85,1.21), hip cartilage defects (PR:1.12 95%CI:
0.88,1.42) and hip ROA (PR:0.94 95%CI: 0.74,1.20) were
not associated with the presence of hip effusion-
synovitis. Nevertheless, any hip BMLs associated with
any hip cartilage defects (PR: 1.22 95%CI 1.06, 1.40) in-
dependent of presence of hip effusion-synovitis. For
these analyses; prevalence ratios (95% confidence inter-
vals) were adjusted for age, sex, body mass index, pres-
ence of hip BMLs, presence of hip cartilage defects as
required and clustering of observations on subjects at
phase 2 and phase 3 was used using Huber-White esti-
mator of variance.
Table 1 Characteristics of the sample population
Characteristics Small or no hip effusion-synovitis (N = 63) Moderate or large hip effusion-synovitis (N = 133) P-value
Age (yrs): mean (SD) 63.4 (4.88) 64.6 (4.97) 0.04
Male sex (%) 46% (29/63) 44% (58/133) 0.75
BMI (kg/cm2): mean (SD) 27.2 (3.11) 28.0 (3.10) 0.02
Hip pain
Presence 33% (19/63) 44% (58/133) 0.04
Severity: mean (SD) 1.82 (5.41) 1.81 (5.45) 0.98
High cartilage signal 52% (33/63) 59% (77/133) 0.20
Presence of any bone marrow lesions (BMLs) 21% (13/63) 15% (20/133) 0.12
Hip cartilage defects
Femoral defects 54% (34/63) 57% (75/133) 0.69
Acetabular defects 68% (42/63) 65% (86/133) 0.61
Any hip defects 71% (44/63) 71% (94/133) 0.92
Presence of radiographic hip OA (ROA) 44% (27/63) 50% (66/133) 0.59
The variable small or no hip effusion-synovitis includes participants with hip effusion-synovitis less than 0.77 cm2 and the variable moderate/large hip effusion
includes participants with effusion-synovitis more than equal to 0.77 cm2
Data presented as means (SD) and proportions
Bold indicates statistically significant results (p < 0.05)
Table 2 Cross sectional associations between presence of hip pain and categories of hip effusion-synovitis
Study factor Presence of hip pain Severity of hip pain
Categories of hip effusion-synovitis Adjusted PR (95%CI)a Ratio of means (95%CI)b
Presence of moderate/large hip effusion-synovitis 1.31 (0.98, 1.74) 0.81 (0.53, 1.08)
Presence of hip effusion-synovitis at two/three sites 1.42 (1.05, 1.93) 0.99 (0.70, 1.40)
Independent variable: presence and severity of hip pain. Dependent variable: hip effusion-synovitis (moderate/large & multiple sites)
The variable small or no hip effusion-synovitis includes participants with hip effusion-synovitis less than 0.77 cm2 and the variable moderate/large hip effusion
includes participants with effusion-synovitis more than equal to 0.77 cm2
aPR (95%CI) = prevalence ratios (95% confidence intervals) adjusted for age, sex, BMI, presence of hip BMLs, presence of cartilage defects and with clustering of
observation on subjects at phase 2 and phase 3 taken into account
bRatio of means (95% confidence intervals) adjusted for age, sex, BMI, presence of hip BMLs, presence of hip cartilage defects and with clustering of observation
on subjects at phase 2 and phase 3 taken into account
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Independent of presence of hip BMLs, hip effusion-
synovitis associated with femoral cartilage defects (βeta:
0.32 95%CI 0.08, 0.56). No other structural or radio-
graphic features of hip showed statistically significant
associations.
Table 3 summarizes the longitudinal association be-
tween change in hip pain and change in hip effusion-
synovitis CSA. Although, resolving hip effusion-synovitis
showed a reduction in hip pain and worsening or per-
sistent hip effusion- synovitis showed an increase in hip
pain these analyses were not statistically significant.
Table 4 outlines the longitudinal associations between
change in effusion-synovitis, any hip BMLs and hip car-
tilage defects. Change in effusion-synovitis was not asso-
ciated with BMLs but increased the risk of incident of
hip cartilage defect by two-folds.
Further longitudinal analyses demonstrated that any
hip BML predicted incident (PR: 1.62 95%CI: 1.13, 2.34)
and worsening hip cartilage defects (PR: 1.50 95%CI:
1.20, 1.86). Conversely, any hip cartilage defect predicted
incident (PR: 1.11 95%CI: 1.03, 1.20) and worsening hip
BMLs (PR: 1.16 95%CI: 1.04, 1.30). These analyses were
independent of presence of hip effusion-synovitis.
Discussion
This prospective cohort study describes the correlates of
hip effusion-synovitis. Overall, there was no association
between hip effusion-synovitis and hip pain. However,
presence of hip effusion-synovitis at multiple sites (pre-
sumably reflecting effusion-synovitis extent) was associ-
ated with the presence of hip pain. Femoral defects were
associated with hip effusion-synovitis CSA. High cartil-
age signal did not associate with hip effusion-synovitis
and contradictory to previous research no relationship
between hip ROA and hip effusion-synovitis was found.
Change in effusion-synovitis increased the risk of hip
cartilage defects.
Cross-sectionally, subjects with a hip effusion- syno-
vitis at multiple sites were 42% more likely to have hip
pain. At the hip, a few studies besides ours have reported
these associations. The first study demonstrated that
older adults with diagnosed hip OA with hip pain in
mid-thigh and pain on palpation had higher odds of
major hip effusion-synovitis [13]. While in the second
study, a weak association was found between hip pain
and grade1 but not grade2 synovitis [14]. The third
found no correlation between hip effusion-synovitis and
hip pain score [16]. Oddly, the fourth study showed
higher prevalence of effusion-synovitis in athletics with
lower hip pain [17] and the last study reported hip pain
and effusion-synovitis were corelated.
These studies lack longitudinal data and measured ef-
fusion or synovitis semi-quantitatively. Also, only one of
the above studies measured synovitis and effusion separ-
ately. While our study has its strengths, we did not as-
sess site-specific hip pain and a cross-sectional
association was found only in subjects who had exten-
sive hip effusion-synovitis. We could not differentiate
between physiological or pathological joint fluid but
overall, it appears that site and extent of effusion-
synovitis at the hip may be relevant for pain in OA.
Cross-sectionally, hip effusion-synovitis size was associ-
ated with femoral cartilage defects. Subsequently, in the
longitudinal analyses, change in hip effusion-synovitis pre-
dicted incident of hip cartilage defects. An association be-
tween hip cartilage defects and hip effusion-synovitis has
not been previously reported but most of the existing evi-
dence for knee OA coincides with our findings. For in-
stance, subjects with large knee effusion(>grade 2) at
baseline had 2.7 times greater risk of cartilage damage at
the end of 30months follow-up [3]. A recent longitudinal
study reported that regional knee effusion-synovitis pre-
dicted knee cartilage defects; cartilage volume loss and
knee BMLs and these associations were largely mediated
by cartilage defects [8]. Hence, causal pathways exist be-
tween knee effusion and knee cartilage defects; and sug-
gests that knee cartilage defects could lead to the
development of BMLs and cartilage volume loss at the
knee joint [8]. Our results are comparable with these find-
ings. Since there are limited number of studies on hip
Table 3 Longitudinal associations between change in presence of hip effusion-synovitis and change in hip pain from baseline to
follow up
Study factor n Change in hip pain Change in hip pain
Adjusted βeta (95% CI)a Further adjusted βeta (95% CI)b
No hip effusion-synovitis 8 Ref Ref
Resolved hip effusion-synovitis 11 −0.20 (−1.51, 1.20) − 0.31 (− 1.82, 1.20)
Worsening or persistent hip effusion-synovitis 174 + 0.32 (− 0.81, 1.46) + 0.30 (− 0.91, 1.52)
Independent variable: change in hip pain. Dependent variable: change in hip effusion-synovitis CSA/size
n = number of observations in the analyses
Bold indicates statistically significant results
CSA cross-sectional area
aβeta co-efficient (95% confidence intervals) adjusted for age, sex and body mass index
bβeta co-efficient (95% confidence intervals) further adjusted for hip BMLs and hip cartilage defects at phase2
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effusion-synovitis the nature of this study is mostly ex-
ploratory and further research is warranted.
Hip BMLs did not associate with hip effusion-
synovitis. Nevertheless, independent of hip effusion-
synovitis hip BMLs predicted worsening and incident of
hip cartilage defects, and vice versa. Increase in hip
effusion-synovitis increased the risk of developing cartil-
age defects.
We speculate that catabolic and proinflammatory me-
diators triggered by synovitis lead to intra-articular deb-
ris due to cartilage breakdown. In turn, presence of
articular debris causes further inflammation of the syno-
vium [1, 2, 4, 11]. Hypothetically, an increase in joint
intra-capsular pressure could push synovitis into the
subchondral bone through the cartilage defects causing
the formation of BMLs. Moreover, BMLs are known to
correlate with not only knee subchondral bone mineral
density (BMD) [37] but also with local hip BMD [38,
39]. Thus, suggesting a causal pathway between hip
effusion-synovitis, hip defects, hip BMLs and alterations
in the bone itself [38, 39]. Moreover, effusion-synovitis is
associated with hip shape [40] and studies show that
those with cam impingement are more likely to have
effusion-synovitis [19, 41].
Limitations
We assessed hip effusion-synovitis quantitatively and
have used similar methods previously [24, 42] and ob-
tained high reproducibility. Nevertheless, the STIR MRI
sequence used to examine joint effusion did not allow
separation of physiological and pathological effusion and
contrast-enhanced technique may yield clearer results.
But our findings match with other MRI-based reports
using similar techniques [13, 16]. Longitudinal analyses
were carried out in a small number of subjects with hip
BMLs. However, our findings were statistically signifi-
cant and coincided with existing literature.
Conclusions
Hip effusion-synovitis at multiple sites (presumably
reflecting extent) may be associated with hip pain. Hip
BMLs and hip cartilage defects are co-dependent and
predict worsening hip effusion-synovitis, indicating
causal pathways between defects, BMLs and effusion-
synovitis.
Together, these factors have a deleterious effect on the
bone and also contribute towards progression of OA.
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Table 4 Longitudinal associations between change in hip effusion-synovitis, any hip BMLs and cartilage defects
Study factor Any hip BMLs Hip Cartilage defects
Resolved Incident Persistent Incident Persistent
Adjusted PR (95%CI) Adjusted PR (95%CI) Adjusted PR (95%CI) Adjusted PR (95%CI) Adjusted PR (95%CI)
Change in hip effusion-synovitis CSA
Model 1 0.65 (0.30, 1.43) 1.31 (0.62, 2.75) 0.94 (0.46, 1.91) 2.23 (1.01, 4.91) 0.99 (0.88, 1.12)
Model 2 0.67 (0.32, 1.39) 1.25 (0.66, 2.33) 0.94 (0.49, 1.80) 2.23 (1.00, 4.97) 1.00 (0.89, 1.33)
Independent variable: presence of structural/ radiographic factors. Dependent variable: change in hip effusion-synovitis size
PR (95%CI) = prevalence ratios (95% confidence intervals)
Mode1 1 = prevalence ratios (95% confidence intervals) adjusted for age, sex, body mass index at phase 2
Mode1 2 = prevalence ratios (95% confidence intervals) adjusted for age, sex, body mass index, presence of hip BMLs, presence of cartilage defects at phase 2
Bold indicates statistically significant results
CSA cross-sectional area
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